Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr Panitumumab vs 18F-FDG PET/MRI in Head and Neck Squamous Cell Carcinoma
NCT05183048Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2023
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zirconium Zr 89 panitumumab in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Alabama at Birmingham. Primary endpoint: Image Quality. Started Feb 2023; status: recruiting.
02
Drugs
zirconium Zr 89 panitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05183048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05183048.